Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tbt Pharma Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is situated within 1 distinct art unit. This indicates a singular point of activity for the company's current prosecution. The presence of 1 pending office action suggests a targeted effort to protect a specific biotechnology innovation.
JOSEPH, JANET is the busiest examiner for the portfolio, with 1 pending office action. This examiner is responsible for the 1 pending action currently active. The progress of this intellectual property matter is tied to the review conducted by this individual examiner. Effective prosecution will require understanding the examiner's specific approach to pharmaceutical applications within the 1 assigned art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOSEPH, JANET | 1 | 40.0% | +51.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18132985 | TOPICAL STATIN FORMULATION FOR TREATMENT OF LICHEN SCLEROSUS AND PSORIASIS | JOSEPH, JANET | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18132985 | TOPICAL STATIN FORMULATION FOR TREATMENT OF LICHEN SCLEROSUS AND PSORIASIS | JOSEPH, JANET | 1611 | §103 | Non-Final OA | — | Pending | Apr 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial